Literature DB >> 12000200

Does depression hurt?

Stephen M Stahl1.   

Abstract

Depression is an illness that causes symptoms in both the body and the brain, i.e., painful physical as well as emotional and vegetative symptoms. Ascending serotonergic and noradrenergic pathways may mediate the emotional and vegetative symptoms of depression and can potentially be targets of serotonin and norepinephrine reuptake inhibitors to obtain relief of these symptoms. Descending serotonergic and noradrenergic pathways may regulate the painful physical symptoms of depression, and when targeted by serotonin and norepinephrine reuptake inhibitors, relieve these symptoms as well. Selective serotonin reuptake inhibitors have a remission rate of 35%, and dual-action reuptake inhibitors have a 45% remission rate. Despite these results, the best treatment of depression currently recognizes the 3 types of symptoms and targets them all for complete remission no matter which drug is used.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12000200     DOI: 10.4088/jcp.v63n0401

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  21 in total

1.  Translating evidence on depression and physical symptoms into effective clinical practice.

Authors: 
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

2.  A novel strategy for dissecting goal-directed action and arousal components of motivated behavior with a progressive hold-down task.

Authors:  Matthew R Bailey; Greg Jensen; Kathleen Taylor; Chris Mezias; Cait Williamson; Rae Silver; Eleanor H Simpson; Peter D Balsam
Journal:  Behav Neurosci       Date:  2015-06       Impact factor: 1.912

3.  The link between depression and physical symptoms.

Authors:  Madhukar H Trivedi
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

4.  [Monoaminergic transmitters in the cerebrospinal fluid of patients with acute, chronic, and intermittent pain. Interface between pain and depression?].

Authors:  M Strittmatter; D Ostertag; K H Hoffmann; C Paulus; C Fischer; S Meyer
Journal:  Nervenarzt       Date:  2005-04       Impact factor: 1.214

5.  In vitro inhibition of recombinant ligand-gated ion channels by high concentrations of milnacipran.

Authors:  Kazuyoshi Ueta; Takahiro Suzuki; Ichiro Uchida; Takashi Mashimo
Journal:  Psychopharmacology (Berl)       Date:  2004-03-02       Impact factor: 4.530

6.  Brain-network mechanisms underlying the divergent effects of depression on spontaneous versus evoked pain in rats: a multiple single-unit study.

Authors:  Ning Wang; Miao Shi; Jin-Yan Wang; Fei Luo
Journal:  Exp Neurol       Date:  2013-10-04       Impact factor: 5.330

7.  Pain associated with specific anxiety and depressive disorders in a nationally representative population sample.

Authors:  Katja Beesdo; Frank Jacobi; Jürgen Hoyer; Nancy C P Low; Michael Höfler; Hans-Ulrich Wittchen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2009-04-10       Impact factor: 4.328

8.  Comparison between the Beck Depression Inventory and psychiatric evaluation of distress in patients on long-term sick leave due to chronic musculoskeletal pain.

Authors:  Patricia Olaya-Contreras; Torgny Persson; Jorma Styf
Journal:  J Multidiscip Healthc       Date:  2010-09-01

9.  Genetic risk score analysis indicates migraine with and without comorbid depression are genetically different disorders.

Authors:  Lannie Ligthart; Jouke-Jan Hottenga; Cathryn M Lewis; Anne E Farmer; Ian W Craig; Gerome Breen; Gonneke Willemsen; Jacqueline M Vink; Christel M Middeldorp; Enda M Byrne; Andrew C Heath; Pamela A F Madden; Michele L Pergadia; Grant W Montgomery; Nicholas G Martin; Brenda W J H Penninx; Peter McGuffin; Dorret I Boomsma; Dale R Nyholt
Journal:  Hum Genet       Date:  2013-10-01       Impact factor: 4.132

10.  Network redundancy analysis of effective brain networks: a comparison of healthy controls and patients with major depression.

Authors:  Lutz Leistritz; Thomas Weiss; Karl-Jürgen Bär; Fabrizio De VicoFallani; Fabio Babiloni; Herbert Witte; Thomas Lehmann
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.